Expert Consensus Opinion 16. Laboratories that require send out of tests for treatment predictive biomarkers should process and send colorectal carcinoma specimens to reference molecular laboratories in a timely manner. Note: It is suggested that a benchmark of 90% of specimens should be sent out within three working days.
Expert Consensus Opinion 17. Pathologists must evaluate candidate specimens for biomarker testing to ensure specimen adequacy taking into account tissue quality, quantity, and malignant tumor cell fraction. Specimen adequacy findings should be documented in the patient report.
Expert Consensus Opinion 18. Laboratories should use colorectal carcinoma molecular biomarker testing methods that are able to detect mutations in specimens with at least 5% mutant allele frequency, taking into account the analytical sensitivity of the assay (limit of detection or LOD) and tumor enrichment (eg, microdissection). Note: It is recommended that the operational minimal neoplastic carcinoma cell content tested should be set at least two times the assay's LOD. 
